NCT04375527 - Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 3, 2020

Primary Completion Date

November 22, 2024

Study Completion Date

November 22, 2024

Conditions

Clinical Stage III Cutaneous Melanoma AJCC V8Clinical Stage IV Cutaneous Melanoma AJCC V8Locally Advanced Cutaneous MelanomaMetastatic Cutaneous MelanomaPathologic Stage III Cutaneous Melanoma AJCC V8Pathologic Stage IIIA Cutaneous Melanoma AJCC V8Pathologic Stage IIIB Cutaneous Melanoma AJCC V8Pathologic Stage IIIC Cutaneous Melanoma AJCC V8Pathologic Stage IIID Cutaneous Melanoma AJCC V8Pathologic Stage IV Cutaneous Melanoma AJCC V8Unresectable Cutaneous Melanoma

Interventions

DRUG

Binimetinib

Given PO

BIOLOGICAL

Nivolumab

Given IV

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

90095

University of California at Los Angeles, Los Angeles